New Intraoperative Nerve Monitoring Device
Launched by SB ISTANBUL EDUCATION AND RESEARCH HOSPITAL · Jul 16, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new device designed to help protect a nerve called the recurrent laryngeal nerve during thyroid and parathyroid surgeries. This nerve is important because it controls your voice, and it can sometimes be accidentally damaged during these types of operations. The goal of the study is to see if this device can reduce the risk of nerve injury and improve patient safety.
People who might be eligible to join the study are adults between 18 and 70 years old who have been diagnosed with thyroid problems, whether cancerous (malignant) or non-cancerous (benign), and who are planning to have surgery. To participate, individuals must be able to give informed consent, meaning they understand the study and agree to take part. People with a history of nerve injury or other neurological conditions will not be eligible. If you join the study, you can expect the new device to be used during your surgery to help monitor and protect the nerve. Currently, the study is not yet recruiting participants, but it aims to include patients of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-70, diagnosis of benign/malignant thyroid disease, informed consent
- Exclusion Criteria:
- • History of previous nerve injury, concomitant neurological disorder
About Sb Istanbul Education And Research Hospital
SB Istanbul Education and Research Hospital is a leading healthcare institution dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Located in Istanbul, Turkey, the hospital combines state-of-the-art facilities with a commitment to education, fostering a collaborative environment for healthcare professionals and researchers. With a focus on a diverse range of therapeutic areas, SB Istanbul Education and Research Hospital aims to contribute to the development of effective treatment options and enhance the overall health outcomes for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported